# Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes

> **NCT03887416** · PHASE4 · UNKNOWN · sponsor: **LM Diagnósticos S.L.** · enrollment: 225 (estimated)

## Conditions studied

- Type2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin 10 MG Oral Tablet [Farxiga]
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03887416
- **Lead sponsor:** LM Diagnósticos S.L.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-12
- **Primary completion:** 2020-02
- **Final completion:** 2020-02
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2019-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03887416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03887416, "Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03887416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*